Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine

Vaccine

Volumn 22, Issue 3-4, 2004, Pages 422-430

  Little, S F ^a   Ivins, B E ^a   Fellows, P F ^a,b   Pitt, M L M ^a   Norris, S L W ^a   Andrews, G P ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Anthrax; Bacillus anthracis; Rabbits; Serological correlate

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

AEROSOL; AMES TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL INFECTION; INFECTION PREVENTION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; SERODIAGNOSIS; SEROLOGY; SINGLE DRUG DOSE;

EID: 0345096575     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.07.004     Document Type: Article

References (32)

1. Friedlander A.M., Pittman P.R., Parker G.W. Anthrax vaccine. Evidence for safety and efficacy against inhalational anthrax. J. Am. Med. Assoc. 282:1999;2104-2106.
2. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., Ingraham N.R. Field evaluation of a human anthrax vaccine. Am. J. Public Health. 52:1962;632-645.
3. Green B.D., Battisti L., Koehler T.M., Thorne C.B., Ivins B.E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immunol. 49:1985;291-297.
4. Mikesell P., Ivins B.E., Ristroph J.D., Dreier T.M. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immunol. 39:1983;371-376.
5. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A.T. Identification of the cellular receptor for anthrax toxin. Nature. 414:2001;225-229.
6. Klimpel K.R., Molloy S.S., Thomas G., Leppla S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10277-10281.
7. Milne J.C., Furlong D., Hanna P.C., Wall J.S., Collier R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:1994;20607-20612.
8. Beall F.A., Dalldorf F.G. The pathogenesis of the lethal effect of anthrax toxin in the rat. J. Infect. Dis. 116:1966;377-389.
9. Stanley J.L., Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Micro. 26:1961;49-66.
10. Friedlander A.M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:1986;7123-7126.
11. Duesbery N.S., Webb C.P., Leppla S.H.et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 280:1998;734-737.
12. Kochi S.K., Schiavo G., Mock M., Montecucco C. Zinc content of the Bacillus anthracis lethal factor. FEMS Microbiol. Lett. 124:1994;343-348.
13. Klimpel K.R., Arora N., Leppla S.H. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Micro. 13:1994;1093-1100.
14. Pellizzari R., Guidi-Rontani C., Vitale G., Mock M., Montecucco C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNg-induced release of NO and TNFa. FEBS Lett. 462:1999;199-204.
15. O'Brien J., Friedlander A., Dreier T., Ezzell J., Leppla S. Effects of anthrax toxin components on human neutrophils. Infect. Immunol. 47:1985;306-310.
16. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U.S.A. 79:1982;3162-3166.
17. -) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immunol. 58:1990;303-308.
18. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immunol. 60:1992;662-668.
19. Ivins B.E., Pitt M.L.M., Fellows P.F.et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in Rhesus macaques. Vaccine. 16:1998;1141-1148.
20. Fritz D.L., Jaax N.K., Lawrence W.B.et al. Pathology of experimental inhalation anthrax in the Rhesus monkey. Lab. Invest. 73:1995;691-702.
21. Gleiser C.A. Pathology of anthrax infection in animal hosts. Fed. Proc. 26:1967;1518-1521.
22. Ivins B.E., Fellows P.F., Pitt M.L.M.et al. Efficacy of a standard human anthrax vaccine against Bacillus anthacis aerosol spore challenge in Rhesus monkeys. Salis Med. Bull. 87:1996;125-126.
23. Zaucha G.M., Pitt M.L.M., Estep J., Ivins B.E., Freidlander A.M. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:1998;982-992.
24. Pitt M.L.M., Little S.F., Ivins B.E.et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 19:2001;4768-4773.
25. Ivins B, Farchaus J, Novak J, et al. Vaccine efficacy of Bacillus anthracis protective antigen produced in prokaryotic and eukaryotic cells. In: Proceedings of the 94th Annual Meeting of American Society of Microbiology, vol. E-38; 1994. p. 150 [abstract].
26. Worsham P.L., Sowers M.R. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can. J. Microbiol. 45:1999;1-8.
27. Farchaus J.W., Ribot W.J., Jendrek S., Little S.F. Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl. Environ. Micro. 64:1998;982-991.
28. Bliss CI. Linear regression. In: Statistics in biology: statistical methods for research in the natural sciences, vol. 1. New York: McGraw-Hill; 1967. p. 152-85.
29. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119:1989;203-210.
30. Pitt MLM, Ivins B, Estep JE, Farchaus J, Friedlander AM. Comparative efficacy of a recombinant protective antigen vaccine against inhalation anthrax in guinea pigs, rabbits, and Rhesus monkeys. In: Proceedings of the 96th Annual Meeting of American Society of Microbiology, vol. E-70; 1996. p. 278.
31. McBride B.W., Mogg A., Telfer J.L.et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine. 16:1998;810-817.
32. Reuveny S., White M.D., Adar Y.Y.et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immunol. 69:2001;2888-2893.